What is TECX's current stock price?

TECX (Tectonic Therapeutic, Inc.) is currently trading at $29.12 with a market cap of $549.5M.

What sector is Tectonic Therapeutic, Inc. in?

Tectonic Therapeutic, Inc. (TECX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TECX a good stock to buy?

Analysts have a Buy consensus on TECX with a price target of $67.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TECX Tectonic Therapeutic, Inc.

Healthcare

$29.12+2.10%ClosedMarket Cap: $549.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.37

P/S

0.00

EV/EBITDA

-3.81

DCF Value

$13.73

FCF Yield

-11.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-32.3%

ROA

-33.9%

ROIC

-39.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-25.2M	$—
Q4 null	$0.00	$-19.2M	$—
FY null	$0.00	$-74.2M	$—
Q3 null	$0.00	$-19.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$67.50

Target (Median)

$67.50

Target Range

$60.00 - $75.00

2 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

Truist SecuritiesBuy

2026-01-08

Trading Activity

Insider Trades

View All

Ruddy Marcella K.officer: Chief Medical Officer

SellWed May 06

Ruddy Marcella K.officer: Chief Medical Officer

SellFri Apr 03

Nader Francoisdirector

SellFri Apr 03

Nader Francois

SellFri Apr 03

Ruddy Marcella K.officer: Chief Medical Officer

SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.21

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

Peers